Add to my reading list Remove from my reading list

US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) has announced that the U.S. Animal and Plant Health Inspection Service has approved a duration of immunity (DOI) claim for Ingelvac® CircoFLEX™ of at least four months for porcine circovirus type 2 (PCV2), the primary pathogen for porcine circovirus associated disease (PCVAD).

According to Klaas Okkinga, marketing manager for Boehringer Ingelheim, the approved DOI label extension substantiates extensive research findings that Ingelvac CircoFLEX provides long-lasting protection from PCV2.

  • "A vaccine that provides at least four months of PCV2 immunity is a significant benefit to producers in protecting pigs, both early and late, from damage caused by this disease," says Okkinga.
  • "Currently, Ingelvac CircoFLEX is the only PCV2 vaccine available with proven DOI of this length when administered as a single-dose to pigs 3 weeks of age or older," Okkinga adds.
  • "Even when administered early, it still protects through the critical period in grow-finish, resulting in reduced pig mortality and improved performance."